Navigation Links
Flexion's Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
Date:5/30/2012

WOBURN, Mass., May 30, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at four weeks* in a Phase 2 proof-of-concept trial. Top-line data showed FX005, delivered intra-articularly to the knee, was well-tolerated and resulted in prolonged improvement in joint pain and function throughout the 12-week duration of the study. These are the first-ever clinical results demonstrating the efficacy of a p38 MAP kinase inhibitor in osteoarthritis patients. Flexion plans to present the complete data set and analyses at an upcoming medical conference.

"There is considerable unmet need for treatments for the pain and damage caused by osteoarthritis," said Timothy McAlindon, chair of rheumatology and professor of medicine at Tufts Medical Center. "In particular, physicians and patients need targeted treatments for osteoarthritis that are more effective and longer lasting. These results represent a significant advance in that direction, so we will eagerly monitor development of this new treatment."

Michael Clayman, M.D., chief executive officer of Flexion, said, "We believe these data not only demonstrate the therapeutic potential of FX005 but also validate Flexion's approach to the treatment of osteoarthritis -- intra-articular delivery of sustained-release therapies providing prolonged activity at the site of disease while minimizing systemic exposure and the corresponding risk of systemic side effects. We are enthusiastic about advancing FX005 into the next phase of clinical development, which will be a Phase 2b dose-ranging study that we plan to initiate in the first half of 2013. The data from that study will then be used to identify an optimal dose for Phase 3."

The trial was a double-blind, placebo-controlled study in which 104 patients were randomized to receive FX005 or placebo via int
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
2. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
3. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
4. Osteoarthritis: Which Treatments Work and Which Dont?
5. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
6. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
7. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
8. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
11. New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... , Sept. 16, 2014 Surgeons at ... describe in a case report the first successful use ... a 13- year-old boy with failing Fontan circulation to ... he was 3 years old, the patient received a ... as functional single ventricle. "The Fontan operation is the ...
(Date:9/16/2014)... Research and Markets has ... Devices Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth ... laparoscopic devices. The report provides a ... applications and industry chain structure. The laparoscopic devices ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Global Laparoscopy Devices Industry Report 2014 2
... 23, 2011 The U.S. Food and Drug Administration ... active ulcerative colitis (UC) in children older than 6 ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... induces and maintains clinical remission in these patients. ...
... ANN ARBOR, Mich., Sept. 23, 2011 Adapting adult medical ... often problematic practice across U.S. hospitals. At the ... and researchers who care for children have been leading the ... test medical devices and curb problems that come from using ...
Cached Medicine Technology:FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 2FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 2University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 4
(Date:9/16/2014)... Centre, NY (PRWEB) September 16, 2014 ... product manufactured by Johnson & Johnson subsidiary Ethicon concluded ... of plaintiff Jo Huskey and awarding her $3.27 million ... According to the Reuters report, “jurors found Ethicon liable ... and their doctors that users were at risk from ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
(Date:9/16/2014)... September 16, 2014 Duke’s Chowder House ... Rebls and Gratafy for a fun evening ... hub is firmly cemented. With the growth of companies in these ... for people who work in tech and at startups to connect ... Gratafy are happy to host events for their peers to meet ...
(Date:9/16/2014)... Treatment with endocrine therapy and radiation therapy as ... of care for women with hormone-receptor positive (HR+) ... at Fox Chase Cancer Center, however, shows that ... populations with the disease. , The results, ... Society for Radiation Oncology,s 56th Annual Meeting on ...
(Date:9/16/2014)... 16, 2014 This year’s theme is ... Sustainable company Glen Mills, Pennsylvania, September 15, 2014- Holganix, ... of the fastest growing companies in the country, produces ... shrub, and tree health-care by naturally decreasing disease and ... Today it announced that it will hold its third ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... who don,t metabolize drug well, , FRIDAY, March 12 (HealthDay ... "black box" warning on its label, alerting patients and doctors ... officials said Friday. , Patients with a certain genetic variation ... puts them at risk for heart attack and stroke, the ...
... with a known sex offender is beginning to settle in as a dark, dark corner of the landscape of life. Slowly we are taking up our routines again, changed by ... ... ... ...
... released the following statement.  , ... , , ... ... "We applaud the steps taken by the Congressional Black Caucus and the White House to meet to discuss the ...
... , ... , ... ... ST. LOUIS , March 12 More than 200 Teamsters and religious leaders held a rally and prayer vigil at Ascension ...
... Award Presented to Joel A. Gingras, Jr. Memorial Fund , ... , , ... ... CHICAGO , March 12 The American Brain Tumor Association (ABTA) presented its first ...
... profitable and industry-leading corporation, LIMU, based in Florida , today announced a brand transformation for 2010.   With ... upcoming international convention March 19 – 20, 2010 in Dallas, Texas . , ... ... , ...
Cached Medicine News:Health News:Plavix Less Effective in Some Patients 2Health News:Plavix Less Effective in Some Patients 3Health News:TypeAMom.net on Keeping Daughters Safe From Predators 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 3Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 4Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 5Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 6Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 7Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 8Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 2Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 3Health News:LIMU Accelerates Growth Era With Brand Transformation 2Health News:LIMU Accelerates Growth Era With Brand Transformation 3
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: